Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study
- PDF / 1,388,339 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 25 Downloads / 210 Views
RESEARCH ARTICLE
Open Access
Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study Hairong He1,2, Hongjun Xie3, Yule Chen3, Chengzhuo Li2, Didi Han2, Fengshuo Xu2 and Jun Lyu1,2,4*
Abstract Background: The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017). Methods: Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level. Results: There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASP, and P = 0.0048 and ρ = 0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally. Conclusion: The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smokingcessation strategies should be strengthened to control the burden associated with BCa. Keywords: Bladder cancer, GBD 2017, Prevalence, Mortality
Background Bladder cancer (BCa) is one of the most-common urological malignancies, and is among the leading causes of cancer deaths worldwide. Approximately 3.0% of all new cancer diagnoses and 2.1% of all cancer deaths are due to BCa [1]. The high incidence, prevalence, mortality, and recurrence rate of BCa indicate that it remains an unsolved clinical and social problem. Two-thirds of patients present * Correspondence: [email protected] 1 Clinical Research Center, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China 2 School of Public Health, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, China Full list of author information is available at the end of the article
with non-muscle-invasive BCa. Although current therapies can achieve a good prognosis, approximately 40% of these patients will progress to muscle-invasive disease after 5 years [2–4]. Moreover, the 5-year survival rate of muscleinvasive BCa is only 60% [5]. Richters A, et al. systematically described the epidemiological characteristics of BCa. They concluded the burden of BCa exhibits obvious regional, sex, and age variations [6]. Specifically, the incidence rate of BCa i
Data Loading...
